Vincamine Periwinkle.
Vincamine Periwinkle supplementation for targeted health support. Increases cerebral blood flow and brain oxygen utilization. Supports cognitive function through improved circulation.
Reviewed March 2026
- Category
- Nootropic
What Vincamine Periwinkle is, and what it does.
- Does it work
- Decent evidence for cerebral circulation benefits. Less studied than vinpocetine. Worth trying for age-related cognitive support.
- How much to take
- Start with 20 to 40mg a day, split across two or three doses because the plasma half-life is short. The 60mg used in research is a study condition.
- Time to feel it
- Most people describe a mild clarity within a couple of hours of a dose. Any steadier change is a four to eight week matter, judged across weeks.
- The first dose
- Subtle, if anything. May notice mild alertness.
- With regular use
- Cognitive benefits typically emerge over 4-8 weeks of consistent use.
- How well tolerated
- Generally well tolerated at normal doses. Blood pressure lowering effect. Interact with blood thinners.
- How it feels
- Gentle mental clarity. Slightly sharper focus. Not stimulating.
- The overlooked benefit
- Vincamine and vinpocetine are different molecules, with vinpocetine made from vincamine in a lab step. A milligram of one is not a milligram of the other.
20 to 40mg a day is where Vincamine Periwinkle works.
Source: European cerebrovascular research; precursor to vinpocetine
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Increases cerebral blood flowCirculation studies
- Supports cognitive functionEuropean clinical trials
- Memory enhancementMixed study results
Questions people ask about Vincamine Periwinkle.
- Is this the same as vinpocetine?
- Related but different. Vinpocetine is a semi-synthetic derivative of vincamine with its own research profile.
- Does it actually work?
- European studies show benefits for cerebral circulation and age-related cognitive issues. US research is more limited.
- Why isn't it more popular?
- Vinpocetine became more popular. Vincamine is harder to source and has more side effect potential.
- Who should try it?
- Older adults with mild cognitive concerns or circulation issues. Not a first-line nootropic for healthy young people.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Vinpocetine is the semi-synthetic ethyl apovincaminate made from vincamine, so the two act through overlapping vasoactive and sodium channel mechanisms. Stacking them adds to one exposure rather than combining two distinct actions.
Both come from Vinca alkaloid chemistry and act on cerebral vascular tone through the same route. A formula carrying both is duplicating one input, not pairing two.
Ginkgolides antagonise platelet activating factor and Vinca alkaloids reduce platelet aggregation in their own right. Combined, the effect on normal clotting adds, which matters most around procedures.
EPA competes with arachidonic acid for cyclooxygenase and shifts eicosanoid output toward less aggregatory forms. Layered on a Vinca alkaloid's own antiplatelet action, the effect on normal clotting is additive.
Allicin-derived sulfur compounds reduce platelet aggregation. Combined with a Vinca alkaloid that does the same, the effects on normal clotting stack.
Vincamine is a vasoactive indole alkaloid, while citicoline works at the level of membrane phospholipid and cholinergic supply. Because the two mechanisms do not overlap, they are stacked in nootropic formulas to cover different steps. No trial has tested the pair, so this is a mechanistic pairing.
Cholinergic precursor loading and vascular alkaloid pharmacology sit on separate pathways, which is the usual reason they appear in the same capsule. Alpha-GPC crosses into the brain readily as a choline source. The combination itself has not been trialled.
The acetyl group carried by acetyl-L-carnitine feeds the same acetylcholine pool that choline donors supply from the other side. Vincamine contributes nothing to that pathway, so the roles are complementary rather than duplicated. Mechanistic rationale only.
Pairing an esterase inhibitor with vincamine puts a cholinergic lever next to a vascular one. Because huperzine A is a genuine enzyme inhibitor with a long duration, stacking it is a decision that deserves dose attention rather than a free addition. No combination data.
Phosphatidylserine acts on membrane composition and signalling rather than on vessel tone, so it is used alongside vincamine as a structural counterpart. The two have not been studied together. Structural and vascular rationales, kept separate.
Two vasodilatory mechanisms in one formula can add up on blood pressure. Vincamine is described as vasoactive and citrulline works through the nitric oxide pathway. This is flagged as an additive cardiovascular effect to watch, not as a benefit claim, and the pair has not been tested together.
Arginine feeds the nitric oxide pathway that lowers vascular resistance. Combined with a vasoactive alkaloid the blood pressure effect may be additive. Worth flagging in any formula that already contains a vasodilator.
Nitrate loading produces a measurable fall in blood pressure through the nitrate-nitrite-nitric oxide route. Adding it to a vasoactive alkaloid stacks two independent vasodilatory mechanisms, though the combination itself has not been trialled. Named here as an interaction to watch rather than a performance pairing.
Pycnogenol is used in vascular formulas for its endothelial effects, which overlap in direction with a vasoactive alkaloid. The combination has not been trialled. The reason to name it is the additive direction, not a claimed benefit.
Caffeine reduces cerebral blood flow acutely while vincamine is taken for the opposite reason, so on that specific measure the two work in opposing directions. Both still raise general arousal. Formulators who put them together should know the vascular directions conflict; the pair has not been studied together.
Vincamine free base has low aqueous solubility, so dissolution is a real constraint on how much is absorbed. A medium-chain triglyceride carrier or simply taking the dose with fat addresses that. This is a formulation point about solubility, not an efficacy claim.
Nootropic stacks that aim at neurotransmitter turnover need the B6-dependent decarboxylation step covered. Vincamine does not participate in that pathway, so B6 is cofactor cover for the rest of the formula. Cofactor logic, no combination evidence.
Nothing specific on file for Vincamine Periwinkle. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Vincamine Periwinkle actually does.
Vincamine is a monoterpenoid indole alkaloid isolated from the leaves of Vinca minor, the lesser periwinkle. It is a natural product, unlike vinpocetine, which is the semisynthetic ethyl ester of apovincaminic acid made from it.
Because vincamine and vinpocetine are chemically distinct, a milligram of one is not a milligram of the other and their pharmacokinetics differ. Labels that use the two names interchangeably are describing different molecules.
The alkaloid free base is weakly basic and poorly water soluble, which is why commercial material is often supplied as a salt such as the tartrate or hydrogen tartrate to improve dissolution.
Vinca minor is a different plant from Catharanthus roseus, the Madagascar periwinkle that yields the vinca dimeric alkaloids. The two share the common name periwinkle and share no relevant alkaloid.
Where Vincamine Periwinkle comes from.
It is a single compound pulled out of periwinkle leaves. The leaves are soaked in solvent, the compound is separated from everything else, then either sold as is or turned into a salt so it dissolves more readily.
Made from a plant. What ends up in the capsule tracks the harvest, so batch testing and a stated marker matter more here than with a made molecule.
Dried leaf and aerial parts of lesser periwinkle, the plant source of the alkaloid.
Milled leaf is extracted with an organic solvent, usually after acid or base adjustment that moves the weakly basic alkaloids between aqueous and organic phases.
Vincamine is separated from the other leaf alkaloids and crystallised to a defined purity.
The purified base may be reacted with tartaric acid to give the hydrogen tartrate salt for higher solubility. This step is optional and defines which form the label declares.
Assayed isolate or standardised extract blended with excipients into a finished dose form.
Labels often do not state whether the material is the free base, the tartrate salt, or a standardised extract, and the three are not interchangeable by weight.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.